Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Brian Calimlim et al.|The Lancet|2021Cited by 538
Topical Simvastatin Accelerates Wound Healing in Diabetes by Enhancing Angiogenesis and LymphangiogenesisJun Asai, Norito Katoh|American Journal Of Pathology|2012Cited by 166
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanomaYasuhiro Fujisawa, Norito Katoh, Shusuke Yoshikawa et al.|Cancer Medicine|2019Cited by 111
Enhanced early skin treatment for atopic dermatitis in infants reduces food allergyKiwako Yamamoto‐Hanada, Naoki Shimojo, T. Kobayashi et al.|Journal of Allergy and Clinical Immunology|2023Cited by 84